Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Albemarle is under pressure amid falling lithium spot and futures prices, with traders concerned about the impact on earnings and guidance. The community is split between expecting more downside and viewing the selloff as a buying opportunity, citing longer-term EV and energy-storage demand.

TGTX has climbed to a fresh 52-week high ahead of expected quarterly results, with traders pointing to BRIUMVIs sales growth and hoping for strong results. Buyout interest and short covering are also prominent theories for the rally, but no acquisition has been confirmed.

Oktas S&P 500 inclusion and repeated earnings beats are drawing attention, but traders are debating whether index-related demand can offset the stocks decline amid weakness across cybersecurity shares. Some attribute the pressure to claims of a DHS data breach involving Okta, though those claims are unverified in the discussion.

CVS is drawing attention over weaker Aetna Medicare Advantage star ratings for 2027, which traders say could reduce quality-bonus revenue and pressure margins. The outlook is debated, with some viewing the ratings decline as a headwind while others question whether the risk is already reflected in the shares.

Fubos steep, volatile decline and repeated lowsoften described by traders as happening without clear company-specific newsdominate the discussion, with attention focused on earnings and CEO Alisa Bowens strategic plan. Bearish traders cite business and dilution concerns, while bulls point to potential Disney/Hulu integration progress and speculate about a rebound or short covering.

Microsofts earnings beat and accelerating Azure growth fueled optimism about AI demand, but the post-earnings gains faded as traders focused on heavy AI infrastructure spending and a new bond offering. The debate centers on whether cloud growth and cash generation will justify the investment, while some traders blame broader weakness in big tech for weighing on the shares.

Updated NSCLC trial data and a shift toward biomarker-selected lung-cancer studies are driving attention, after the broader patient group showed a more modest response and durability remains immature, with a supplemental filing now planned for 2027. Traders are divided: some see the strong subgroup results as a promising precision-treatment strategy, while others focus on the narrower opportunity, longer timeline, and managements unclear presentation.

A steep selloff in CleanSpark and other bitcoin-mining and data-center stocks is dominating discussion, with traders citing sector weakness, debt and interest-rate concerns, and CLSKs lagging performance despite comparatively resilient bitcoin prices. Bulls point to the Meta data-center lease and the companys bitcoin holdings, while bears remain focused on leverage, management, and continued downside.

Accentures rally is drawing attention after CEO Julie Sweet and a director disclosed open-market share purchases, which some traders view as a confidence signal. Others are taking profits or warning that the stocks sharp run may be overextended.

CELH is drawing attention for its recent strength as traders discuss money rotating out of tech and look ahead to Q3 earnings. Sentiment is split between hopes for improving sales, Alani Nu growth and stronger recent Nielsen data, and concerns about weakness in the core Celsius brand, margins and management execution.